Indian drug makers to drop Bradley bids

Count Indian drug makers Ranbaxy and Dr. Reddy's out of the bidding for Bradley Pharmaceuticals. The two companies entered non-binding bids of around $250 million to $300 million--much lower than those submitted by U.S. firms.

Bradley began accepting bids last month, saying it would definitely pursue a buyout. The company's market cap is around $330 million.

- read the report from India's Business Standard

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

THIS WEEK: Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today!

Suggested Articles

North Korean hackers were accused of posing as corporate recruiters in a scheme to breach AstraZeneca's computer systems and steal COVID-19 research.

The FDA has delayed its review of Revance's frown-line injection candidate after it failed to inspect a key manufacturing facility on time.

McKinsey & Company helped guide Purdue's strategy for years and pitched the idea of rebates to distributors for overdoses, according to the NYT.